AXT (AXTI) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 revenue reached $27.9 million, up 23% sequentially and 50% year-over-year, driven by strong demand for indium phosphide, gallium arsenide, and germanium substrates, especially in AI, data center, and optical network applications.
Gross profit rose to $7.7 million, with gross margin improving to 27.4% from 9.2% in Q2 2023, reflecting higher unit volumes and favorable product mix.
Non-GAAP net loss narrowed to $0.8 million ($0.02/share), and GAAP net loss was $1.5 million ($0.04/share), both improving significantly year-over-year.
The company continues to pursue the IPO of its subsidiary Tongmei on the STAR Market in China, with the process under regulatory review and positive feedback from the exchange.
Management highlighted tangible signs of market recovery and successful execution in a dynamic technology landscape.
Financial highlights
Q2 2024 revenue: $27.9 million, up from $22.7 million in Q1 2024 and $18.6 million in Q2 2023.
Gross margin: 27.4% (GAAP), up from 9.2% in Q2 2023; non-GAAP gross margin: 27.6%.
Non-GAAP operating loss: $1.2 million; GAAP operating loss: $1.9 million, both improved year-over-year.
Cash, equivalents, and investments: $43.3 million as of June 30, 2024; cash and cash equivalents: $27.8 million; short-term investments: $1.7 million.
Inventory at June 30, 2024: $85.8 million, with reserves for excess and obsolete inventory at $23.1 million.
Outlook and guidance
Q3 2024 revenue expected between $25.0 million and $27.0 million.
Non-GAAP net loss projected at $0.06–$0.08/share; GAAP net loss at $0.07–$0.09/share.
Management expects continued growth opportunities in AI and optical transceivers, with some quarter-to-quarter variability as end markets normalize.
The company believes it has adequate cash and investments to meet operating needs and capital expenditures over the next 12 months.
Indium phosphide and raw material revenues expected to hold steady; gallium arsenide and germanium to moderate due to order timing and inventory digestion.
Latest events from AXT
- Key votes include director elections, say-on-pay, auditor ratification, and share authorization increase.AXTI
Proxy filing20 Mar 2026 - AI-driven demand is fueling record backlog and capacity expansion, but export permits are the main bottleneck.AXTI
Q4 202519 Feb 2026 - Expanding indium phosphide capacity and targeting power amplifier growth with strong supply chain control.AXTI
27th Annual Needham Growth Conference3 Feb 2026 - Q3 revenue up 36% to $23.6M, margin at 24%, net loss narrows to $2.9M.AXTI
Q3 202417 Jan 2026 - AI-driven demand is doubling indium phosphide needs, with capacity and market share set to rise.AXTI
28th Annual Needham Growth Conference Virtual14 Jan 2026 - 31% revenue growth in 2024, but export controls to delay $4–$5M in Q1 sales.AXTI
Q4 202424 Dec 2025 - Registering up to $100M in securities, with China-based operations and no planned dividends.AXTI
Registration Filing16 Dec 2025 - Annual meeting to vote on director, compensation, equity plan, and auditor amid strong 2024 results.AXTI
Proxy Filing1 Dec 2025 - Key votes on director, executive pay, equity plan, and auditor set for May 15, 2025.AXTI
Proxy Filing1 Dec 2025